In silico and in vitro assessment of androgen receptor antagonists

dc.contributor.authorSerçinoğlu, Oğlu
dc.contributor.authorBereketoglu, Ceyhun
dc.contributor.authorOlsson, Per-Erik
dc.contributor.authorPradhan, Ajay
dc.date.accessioned2025-10-29T11:29:39Z
dc.date.issued2021
dc.departmentFakülteler, Mühendislik Fakültesi, Biyomühendislik Bölümü
dc.description.abstractThere is a growing concern for male reproductive health as studies suggest that there is a sharp increase in prostate cancer and other fertility related problems. Apart from lifestyle, pollutants are also known to negatively affect the reproductive system. In addition to many other compounds that have been shown to alter androgen signaling, several environmental pollutants are known to disrupt androgen signaling via binding to androgen receptor (AR) or indirectly affecting the androgen synthesis. We analyzed here the molecular mechanism of the interaction between the human AR Ligand Binding Domain (hAR-LBD) and two environmental pollutants, linuron (a herbicide) and procymidone (a pesticide), and compared with the steroid agonist dihydrotestosterone (DHT) and well-known hAR antagonists bicalutamide and enzalutamide. Using molecular docking and dynamics simulations, we showed that the co-activator interaction site of the hAR-LBD is disrupted in different ways by different ligands. Binding free energies of the ligands were also ordered in increasing order as follows: linuron, procymidone, DHT, bicalutamide, and enzalutamide. These data were confirmed by in vitro assays. Reporter assay with MDA-kb2 cells showed that linuron, procymidone, bicalutamide and enzalutamide can inhibit androgen mediated activation of luciferase activity. Gene expression analysis further showed that these compounds can inhibit the expression of prostate specific antigen (PSA) and microseminoprotein beta (MSMB) in prostate cell line LNCaP. Comparative analysis showed that procymidone is more potent than linuron in inhibiting AR activity. Furthermore, procymidone at 10 mu M dose showed equivalent and higher activity to AR inhibitor enzalutamide and bicalutamide respectively.
dc.description.sponsorshipKnowledge Foundation Sweden
dc.description.sponsorshipO.E and Edla Johanssons Scientific Foundation, Sweden
dc.description.sponsorshipOdrebro University
dc.description.sponsorshipThis research was funded by Knowledge Foundation Sweden, O.E and Edla Johanssons Scientific Foundation, Sweden and Odrebro University.
dc.identifier.doi10.1016/j.compbiolchem.2021.107490
dc.identifier.issn1476-9271
dc.identifier.issn1476-928X
dc.identifier.orcid0000-0003-1361-8160
dc.identifier.orcid0000-0003-2305-8574
dc.identifier.orcid0000-0001-7336-6335
dc.identifier.orcid0000-0001-9400-7892
dc.identifier.pmid33932781
dc.identifier.scopus2-s2.0-85105696706
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.compbiolchem.2021.107490
dc.identifier.urihttps://hdl.handle.net/20.500.14854/11204
dc.identifier.volume92
dc.identifier.wosWOS:000663513100008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofComputational Biology and Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20251020
dc.subjectHelix 12
dc.subjectAntiandrogen
dc.subjectProstate
dc.subjectEndocrine disruption
dc.subjectPollutants
dc.titleIn silico and in vitro assessment of androgen receptor antagonists
dc.typeArticle

Dosyalar